Key Developments: Prana Biotechnology Ltd (PRAN.O)

PRAN.O on Consolidated Issue listed on NASDAQ Capital Market

1.87USD
19 Dec 2014
Price Change (% chg)

$-0.03 (-1.58%)
Prev Close
$1.90
Open
$1.88
Day's High
$1.95
Day's Low
$1.82
Volume
257,919
Avg. Vol
374,679
52-wk High
$13.29
52-wk Low
$1.40

Search Stocks

Latest Key Developments (Source: Significant Developments)

Prana Biotechnology Limited announces appointment of Chief Financial Officer
Monday, 3 Nov 2014 08:00pm EST 

Prana Biotechnology Limited:Announces appointment of Kathryn Andrews as Chief Financial Officer (CFO).Says the appointment follows the resignation of Richard (Rick) Revelins from the role of CFO and company secretary to pursue other commercial interests in the USA.  Full Article

Prana Biotechnology Limited does not declare dividend
Tuesday, 30 Sep 2014 04:20am EDT 

Prana Biotechnology Limited:Says no dividends were paid or recommended during the financial year ended June 30.  Full Article

Prana Biotechnology Ltd receives FDA orphan drug designation for PBT2 for huntington disease
Thursday, 4 Sep 2014 11:33pm EDT 

Prana Biotechnology Ltd:Say that US Food and Drug Administration (FDA) has granted orphan drug designation to PBT2 for treatment of huntington disease.Orphan drug designation is granted by FDA to promote development of drugs for diseases affecting less than 200,000 people in the United States.Orphan drug designation entitles Prana to seven years of market exclusivity for use of PBT2 in treatment of huntington disease;.Protocol assistance by FDA to optimize drug development in preparation of dossier that will meet regulatory requirements; and reduced fees associated with applying for market approval.Says that it will also be applying for orphan drug designation in Europe and other jurisdictions.  Full Article

Prana Biotechnology Ltd does not declare dividend
Friday, 29 Aug 2014 03:17am EDT 

Prana Biotechnology Ltd:Group resolved not to declare any dividends in the year ended June 30, 2014.  Full Article

Prana Biotechnology announces issue of ordinary shares
Monday, 7 Apr 2014 03:38am EDT 

Prana Biotechnology Ltd:Issues 59,171,610 ordinary shares.To fund Prana Biotechnology current clinical development, research programs and working capital.Says total consideration is A$16,378,781.  Full Article

Prana Biotechnology announces preliminary results of Phase 2 trial of PBT2
Monday, 31 Mar 2014 02:55am EDT 

Prana Biotechnology Ltd:Says PBT2 did not meet its primary endpoint of a statistically significant reduction in the levels of beta-amyloid plaques in the brains of prodromal/mild Alzheimer’s disease patients, as measured using PiB-PET Standardized Uptake Value Ratio (SUVR).Whilst there was a reduction in the overall levels of the PiB PET signal in patients treated with PBT2, the results were confounded by an atypical reduction of levels of the PiB PET signal in the placebo group as well.  Full Article

Prana Biotechnology Ltd's disease treatment strategy validated by independent study
Wednesday, 5 Mar 2014 09:30pm EST 

Prana Biotechnology Ltd:Says it has commented on the publication of a study in the current issue of the peer-reviewed journal Proceedings of the National Academy of Sciences USA (PNAS).Says the findings demonstrated a dose dependent relationship between copper levels and oligomerisation of Amyloid-β peptide (Aβ) resulting in toxicity.Says Clioquinol, Prana’s proof of concept Metal Protein Attenuating Compound, rescued the metal induced Aβ toxicity, a finding consistent with the proposed mechanism of action of Prana’s PBT2.  Full Article

Prana Biotechnology Ltd's board does not declare dividend
Wednesday, 26 Feb 2014 12:54am EST 

Prana Biotechnology Ltd:No dividend has declared for the half year ended Dec. 31, 2013.  Full Article

Prana Biotechnology Ltd announces successful phase 2 results in huntington disease trial
Tuesday, 18 Feb 2014 01:03am EST 

Prana Biotechnology Ltd:Says results of its Reach2HD Phase 2 clinical trial investigating PBT2 as a treatment for Huntington disease.The double-blind, placebo-controlled study was conducted by the Huntington Study Group at research sites in the United States and Australia.The study enrolled 109 individuals with Huntington disease who were randomly assigned to receive daily doses of either PBT2 250mg, PBT2 100mg, or placebo for 26 weeks.The primary endpoint of the study was met.In this study, PBT2 was safe and well tolerated, 95 pct (104 of 109) of participants completed the study on their assigned dose.An independent Data Safety Monitoring Board met on five occasions over the course of the trial and on each occasion recommended that the trial continue as per the original protocol.There were no substantial differences in adverse events across the two PBT2 dose groups and the placebo group.  Full Article

Prana Biotechnology Ltd announces issue of shares and options
Friday, 7 Feb 2014 12:30am EST 

Prana Biotechnology Ltd:Issues 3,928,900 and 50,000 ordinary shares at the issue price of A$884,003 and A$12,500 respectively.Issues 100,000 fully vested and 200,000 vest upon performance milestone unlisted options.Says purpose of the issue is to exercise of unlisted options PBTAI and PBTAW.  Full Article

US STOCKS-Wall St flat following weak payrolls report

* Dow up 0.06 pct, S&P up 0.05 pct, Nasdaq off 0.07 pct (Updates to midday)

Search Stocks